Wegovy weight loss by month: reading the real trial data

Month one: adjustment, not acceleration

The first four weeks on Wegovy are largely about your body settling into the medicine. Treatment starts at 0.25mg, a tolerability dose whose purpose is to reduce the nausea and digestive discomfort that a therapeutic dose would otherwise cause upfront. At 0.25mg, appetite suppression is mild and most people see only modest weight change, if any. That's expected, not a warning sign.

The NHS semaglutide page notes that the escalation schedule runs roughly every four weeks: 0.25mg, then 0.5mg, then 1mg, then 1.7mg, then the 2.4mg maintenance dose. So for much of the first month, the dose is still sub-therapeutic. People searching for Wegovy weight loss in a month are sometimes discouraged by slow early movement, and understanding what one month on Wegovy typically looks like can help explain why the dose schedule, rather than the medicine not working, is usually the reason. A detailed look at what to expect after the first month can ground those expectations more precisely.

Side effects (mainly nausea, constipation, and tiredness) tend to be most noticeable during early dose increases and often settle within days to a couple of weeks. They don't affect everyone the same way.

Months two to six: where most of the weight loss happens

Once the dose has been climbing for a few weeks, appetite changes become more pronounced. Most people notice a real reduction in hunger and a lower appetite for calorie-dense foods from around months two or three. The STEP 1 data showed meaningful weight loss building steadily across this period, with a significant proportion of the total loss occurring before the six-month mark.

For a closer look at what trial participants and clinical-practice patients typically see across a full half-year, Wegovy's six-month weight-loss data is worth reading alongside this page. The three-month picture (often the first point where both patients and prescribers pause to assess progress) is explored in more detail on the three-month results page. NICE's appraisal of semaglutide (TA875) notes that if less than 5% weight loss has been achieved after six months on the maintenance dose, continuing treatment should be reviewed, so that six-month window is genuinely clinically significant, not arbitrary.

The dose you reach matters too. Not everyone titrates to 2.4mg; some stabilise at a lower dose if side effects are a limiting factor. The weight loss at 1.7mg, for example, is meaningful but typically lower than at the full maintenance dose.

Beyond six months: slower progress, sustained results

Weight loss tends to plateau after around 60–68 weeks. That's not failure, it's how GLP-1 medicines work. The body reaches a new equilibrium. The STEP 1 trial's average of roughly 15% body weight lost was measured at that plateau point, not at peak early loss.

For people who find that plateau frustrating or who didn't tolerate the full dose, the newer 7.2mg maintenance option (approved by the MHRA in April 2026) offers an additional rung. Trial data for that dose reported an average of around 20.7% weight loss over 72 weeks. That's explored fully on the Wegovy treatment overview page. It's also worth knowing that tirzepatide (Mounjaro) is a dual GIP and GLP-1 receptor agonist (a different mechanism) and shows a somewhat higher average weight loss in head-to-head data; the weight-loss treatment options page sets out how the two compare for people weighing up choices.

One practical note on timing: the dose titration schedule means starting in the middle of a busy stretch (a holiday, a period with irregular meals, a month of disrupted routine) can make the early GI adjustment harder. Quite a few patients tell us they deliberately time their first pen for a quieter period, a Monday order, or just after payday when routine feels more settled. It's not a medical requirement, but it's sensible.

What shapes your own month-by-month results

Trial averages are population figures. Individual weight loss by month will depend on where you start (people with higher starting weights often see larger absolute losses early), which dose you reach, how well you tolerate titration, and what changes you make to eating patterns and activity. Semaglutide suppresses appetite; it doesn't replace the behavioural side of weight management.

Protein intake, hydration and some form of resistance or weight-bearing activity all matter more, not less, when you're eating significantly less. A prescriber or dietitian can help you build a plan around treatment rather than alongside it as an afterthought. The semaglutide information page covers the clinical background in more detail, and the FAQs address a range of practical questions our prescribers hear regularly.

If you're weighing up whether Wegovy is the right option for your situation, speaking to our prescribers is the clearest next step. Every consultation at nume is reviewed the same day by a GPhC-registered prescriber (a real clinician assessing your case, not an automated system) and there are no subscriptions or hidden costs involved.